PREZCOBIX™ (darunavir/cobicistat) Approved in the U.S. for the Treatment of...
PREZCOBIX(TM) (darunavir 800mg / cobicistat 150mg) Tablets Facebook Twitter Pinterest PREZCOBIX(TM) (darunavir 800mg / cobicistat 150mg) Bottle Facebook Twitter Pinterest PREZCOBIX(TM) Logo Facebook...
View ArticleYour Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV...
(Source: Johnson & Johnson) Notable HIV Advocates Highlight Perspectives of People Living with or Affected by HIV to Leverage Shared Support and Self-Expression TITUSVILLE, N.J., September 8, 2015...
View ArticleYour Story, Your HIV Wisdom™ Brings Together HIV Voices and Supports HIV...
TITUSVILLE, N.J., Sept. 8, 2015 /PRNewswire/ -- Seeking and sharing information are important parts of the HIV journey – in fact, 80 percent of people living with HIV said they give advice or tell...
View ArticlePREZCOBIX™ (darunavir/cobicistat) Approved in the U.S. for the Treatment of...
(Source: Johnson & Johnson) Combined Fixed-Dose Tablet of Darunavir and Cobicistat Can Help Reduce Number of Pills in a Combination Antiretroviral Treatment Regimen TITUSVILLE, NJ, January 29, 2015...
View ArticleU.S. FDA Approves PREZISTA® (darunavir) for Use in Pregnant Women with HIV...
(Source: Johnson & Johnson) Data shows PREZISTA is a safe and effective treatment option in pregnant women, with no reports of mother-to-child HIV transmission among women who continued therapy...
View ArticleTECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA...
(Source: AbbVie Inc) - TECHNIVIE provides an opportunity to treat adults in the U.S. who have genotype 4 (GT4) chronic hepatitis C virus (HCV) infection without cirrhosis, a population historically...
View ArticleTECHNIVIE(TM) (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA...
- TECHNIVIE provides an opportunity to treat adults in the U.S. who have genotype 4 (GT4) chronic hepatitis C virus (HCV) infection without cirrhosis, a population historically considered...
View ArticleTECHNIVIE™ (ombitasvir, paritaprevir, and ritonavir tablets) Receives FDA...
NORTH CHICAGO, Ill., July 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global, research-based biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved...
View ArticleAbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive...
(Source: AbbVie Inc) AbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive Disease Week® (DDW) 2015 - May 12, 2015 IT STARTS WITH SCIENCE AND ENDS WITH A NEW WAY FORWARD -...
View ArticleAbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive...
NORTH CHICAGO, Ill., May 12, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that 18 abstracts in its gastroenterology and hepatology programs will be presented at Digestive Disease Week® (DDW)...
View ArticleU.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral,...
(Source: AbbVie Inc) - The New Drug Application (NDA) was accepted by the U.S. Food and Drug Administration (FDA) and is based on results from the PEARL-I study, which demonstrated up to 100 percent...
View ArticleAbbVie Receives Health Canada Approval of HOLKIRA™ PAK for the Treatment of...
New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for genotype 1 hepatitis C patients In Phase 3 clinical trials, HOLKIRA PAK (with or without ribavirin) cured an...
View ArticleAbbVie Receives Health Canada Approval of HOLKIRA™ PAK for the Treatment of...
New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for genotype 1 hepatitis C patients In Phase 3 clinical trials, HOLKIRA PAK (with or without ribavirin) cured an...
View ArticleAbbVie Demonstrates Commitment to Continued Research in Hepatitis C with...
NORTH CHICAGO, Ill., Oct. 1, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from its ongoing Phase 1 through Phase 3 hepatitis C clinical development programs will be presented at The...
View ArticleEnanta Pharmaceuticals Announces Data Presentations on Regimens Containing...
(Source: Enanta Pharmaceuticals Inc) Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitors Paritaprevir and ABT-493 at The International Liver Congress™ 2015...
View ArticleEnanta Announces SVR12 results of 95% from AbbVie’s GIFT-1 Study in...
(Source: Enanta Pharmaceuticals Inc) Sustained virologic response 12 weeks post-treatment (SVR12) of 91 percent was achieved in Japanese patients with genotype 1b (GT1b) hepatitis C virus (HCV)...
View ArticleAbbVie Presents New Data for its Investigational Hepatitis C Treatment in...
(Source: AbbVie Inc) - Primary endpoint of 95 percent and secondary endpoint of 91 percent SVR12 achieved in genotype 1b hepatitis C virus infected Japanese patients without and with compensated...
View ArticleAbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives...
NORTH CHICAGO, Ill., Sept. 28, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved...
View ArticleAbbVie Demonstrates Commitment to Continued Research in Hepatitis C with...
NORTH CHICAGO, Ill., Oct. 1, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from its ongoing Phase 1 through Phase 3 hepatitis C clinical development programs will be presented at The...
View ArticleAbbVie Demonstrates Commitment to Continued Research in Hepatitis C with...
(Source: AbbVie Inc) Data from 25 accepted abstracts include results from: -- AbbVie's investigational treatment in liver transplant recipients with recurrent genotype 1 (GT1) chronic hepatitis C virus...
View Article